VAL.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 10:12):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

Stats
Dagens volum	154 542
Gjennomsnittsvolum	1.86M
Markedsverdi	4.17M
EPS	£-0.00980 ( Q4 \| 2023-12-31 )
Neste inntjeningsdato	( £0 ) 2024-08-21
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.570 (Sector) 0 (Industry) 0
ATR14	£0.0990 (3.14%)

AMYT.L -11.73%

APH.L 0.51%

AVCT.L 1.59%

AZN.L -0.29%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 2.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.08%

FUM.L 1.58%

GDR.L 2.97%

GNS.L 1.45%

GSK.L -0.56%

HCM.L -0.36%

HEMO.L 0.53%

HIK.L -0.48%

IMM.L -1.15%

INDV.L 0.40%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.48%

NFX.L -4.71%

OBD.L 0.92%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.75%

OVB.L -15.56%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 1.54%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 6.96%

SCLP.L -1.81%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

Korrelasjon (AI algo v.1.1b): Overvalued: -0.15% £3.15 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

ValiRx PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ValiRx PLC Økonomi

Annual	2023
Omsetning:	£9 600.00
Bruttogevinst:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2023
Omsetning:	£9 600.00
Bruttogevinst:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2022
Omsetning:	£0
Bruttogevinst:	£-224 268 (0.00 %)
EPS:	£-0.0311

FY	2021
Omsetning:	£0.00
Bruttogevinst:	£0.00 (0.00 %)
EPS:	£-0.0401

Financial Reports:

No articles found.

ValiRx PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ValiRx PLC

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.